Salix Pharmaceuticals (NASDAQ: SLXP) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its peers? We will compare Salix Pharmaceuticals to similar businesses based on the strength of its dividends, earnings, profitability, valuation, institutional ownership, analyst recommendations and risk.
Volatility & Risk
Salix Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Salix Pharmaceuticals’ peers have a beta of 1.12, meaning that their average stock price is 12% more volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for Salix Pharmaceuticals and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Salix Pharmaceuticals Competitors||69||335||989||29||2.69|
As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 22.98%. Given Salix Pharmaceuticals’ peers higher probable upside, analysts clearly believe Salix Pharmaceuticals has less favorable growth aspects than its peers.
This table compares Salix Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Salix Pharmaceuticals Competitors||-581.63%||-63.32%||-26.72%|
Valuation & Earnings
This table compares Salix Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Salix Pharmaceuticals Competitors||$3.02 billion||$642.98 million||-87.01|
Salix Pharmaceuticals’ peers have higher revenue and earnings than Salix Pharmaceuticals. Salix Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
64.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 10.7% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Salix Pharmaceuticals peers beat Salix Pharmaceuticals on 7 of the 8 factors compared.
Salix Pharmaceuticals Company Profile
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.
Receive News & Ratings for Salix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.